TargetRx offers member physicians an online forum to share their attitudes and beliefs with pharmaceutical companies through surveys and other market research activities. Since physicians are on the front-line of the practice of medicine everyday, gauging the effectiveness of existing therapies and identifying the need for new treatments, they are in the best position to provide guidance to pharmaceutical companies on developing, promoting and positioning drugs responsibly and for the right types of patients.

Because TargetRx is dedicated to improving the exchange of information between physicians and pharmaceutical companies, membership is only available to licensed physicians in the United States. Membership is free. As a member, you’ll have the opportunity to participate in market research programs related to your medical specialty. You will be compensated for sharing your expertise, and your confidentiality will be fully respected.

Financials

Date Type Amount Investors Valuation
04/01/08 Series D 9.6M Unknown

People

Phillip Gerbino (Board Member)

Jim Lim (Board Member)

Charles Newhall (Board Member)

Stuart Samuels (Board Member)

Patrick Howie (VP New Product Development)

View more details about all 16 people at TargetRx

News

Life-science briefing: Monday, April 7, 2008

April 7, 2008 10:49 pm

TODAY’S HEADLINES: Quark Pharma gets $27M for RNAi drugs (release) TargetRx takes in $9.6M for physician-prescribing data (release) D-Pharm raises… Continue reading ⟩

Life sciences briefing: Tuesday, Jan. 29, 2008

January 29, 2008 6:12 pm

TODAY’S HEADLINES: Immune-system specialty pharma Circassia raises £11M (release) Cancer-biomarker biotech CS-Keys takes in $6.3M (release) Neuro-robotic device maker Myomo… Continue reading ⟩